Ribociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Cancer
3h agoen
Source
OncoDailyRibociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Canceroncodaily.comFor patients with hormone receptor-positive, HER2-negative metastatic breast cancer, endocrine therapy combined with a CDK4/6 inhibitor has become a central first-line standard. The question is no longer whether CDK4/6 inhibition […]
You might also wanna read
Breast Cancer Treatment Strategies: AI ± CDK4/6 Inhibitors, Biomarkers, and ESR1 Mutations
This article appears to be a medical education piece focused on breast cancer treatment strategies, specifically discussing patients progres
mdsc.pe·15d ago
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy
doi.org·1d ago
Targeting genomic instability: From chemotherapy to precision medicine in cancer treatment
This article examines genomic instability as a hallmark of cancer, explaining how it drives malignant transformation through accumulated gen
cell.com·24d ago
Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis
doi.org·18d ago
Ask HN: What is the latest on treatment of Metastatic Breast Cancer?
news.ycombinator.com·1y ago
Compound UNI418 disrupts cancer DNA repair to overcome drug resistance
Researchers have discovered that cancer cells survive DNA-damaging treatments by using sophisticated repair systems like homologous recombin
sciencedaily.com·22d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.